<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05610384</url>
  </required_header>
  <id_info>
    <org_study_id>MD-246-2022</org_study_id>
    <nct_id>NCT05610384</nct_id>
  </id_info>
  <brief_title>Ibuprofen Versus Ketorolac for Perioperative Pain Control After Open Hysterectomy</brief_title>
  <official_title>Intravenous Ibuprofen Versus Ketorolac for Perioperative Pain Control After Open Hysterectomy: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the analgesic effect of intravenous ibuprofen to&#xD;
      ketorolac for pain control after open hysterectomy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thirty minutes before the surgery, all patients will receive 1 gm paracetamol intravenously&#xD;
      then every 6 hours postoperatively.&#xD;
&#xD;
      A research assistant is responsible for opening the envelopes, group assignment and drug&#xD;
      preparation (the three doses will be prepared and marked with the patient's name as well as&#xD;
      the time of administration) without any further involvement in the study. The patient,&#xD;
      attending anesthetist, nurse and data collector will be blinded to the administered drug.&#xD;
&#xD;
      Upon arrival to the operating room, routine monitors (electrocardiogram, pulse oximetry, and&#xD;
      non-invasive blood pressure monitor) will be applied; intravenous line will be secured, and&#xD;
      prophylactic antiemetic will be provided in the form of slow intravenous injection of 8 mg&#xD;
      dexamethasone drugs.&#xD;
&#xD;
      Anesthesia Anesthesia will be induced with 2 mg/kg propofol, 1 mcg/kg fentanyl, and tracheal&#xD;
      intubation will be facilitated by 0.5 mg/kg atracurium after loss of consciousness.&#xD;
      Anesthesia will be maintained with isoflurane 1-1.2% in oxygen and 0.1 mg/kg atracurium every&#xD;
      20 minutes. Intraoperative analgesia will be in the form of 1 mcg/kg fentanyl boluses as&#xD;
      needed.&#xD;
&#xD;
      Postoperatively, pain assessments using the visual analogue scale (VAS) will be performed at&#xD;
      rest and during movement (knee flexion) at 0.5, 2, 4, 6, 10, 18, and 24 h after leaving the&#xD;
      operating room. If the VAS score is &gt; 3 intravenous titration of 2 mg morphine given slowly&#xD;
      to be repeated after 30 minutes if pain persisted.&#xD;
&#xD;
      Intravenous ondansetron 4 mg will be given to treat postoperative nausea or vomiting&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2022</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mean dynamic VAS</measure>
    <time_frame>24 hour after surgery</time_frame>
    <description>average postoperative VAS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>static VAS</measure>
    <time_frame>30 minutes, 2, 4, 6, 10, 18, 24 hours postoperatively</time_frame>
    <description>a 10cm line, with two end points representing 0 ('no pain') and 10 ('pain as bad as it could possibly be')</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>dynamic VAS</measure>
    <time_frame>procedure (during knee flexion)</time_frame>
    <description>a 10cm line, with two end points representing 0 ('no pain') and 10 ('pain as bad as it could possibly be')</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to first analgesia requirement</measure>
    <time_frame>period from extubation until first analgesic requirement during the first 24 hour postoperatively</time_frame>
    <description>hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>morphine consumption</measure>
    <time_frame>during the first 24 hour postoperatively</time_frame>
    <description>mg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to independent movement</measure>
    <time_frame>during the first 24 hour postoperatively</time_frame>
    <description>time from extubation to be able independently mobile e.g. using the bathroom</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patients satisfaction</measure>
    <time_frame>at the end of 24 hour postoperative</time_frame>
    <description>on scale of 0 to 10</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Postoperative Pain</condition>
  <condition>Hysterectomy</condition>
  <arm_group>
    <arm_group_label>Ketorolac group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ketorolac 30 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibuprofen group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ibuprofen 800 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac Injectable Solution</intervention_name>
    <description>ketorolac 30 mg (diluted in 200 mL normal saline) intravenously over 5 minutes before induction of anesthesia then every 8 hours postoperatively</description>
    <arm_group_label>Ketorolac group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen 800 mg</intervention_name>
    <description>ibuprofen 800 mg intravenously (Diluted in 200 mL of normal saline) over 5 minutes before induction of anesthesia then every 8 hours postoperatively.</description>
    <arm_group_label>Ibuprofen group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  adult (40-65 years)&#xD;
&#xD;
          -  ASA I-II women&#xD;
&#xD;
          -  scheduled to undergo open elective abdominal hysterectomy with or without&#xD;
             salpingo-oophorectomy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  renal impairment,&#xD;
&#xD;
          -  allergy to any of study's drugs,&#xD;
&#xD;
          -  history of gastrointestinal bleeding or ulceration, or inflammatory bowel disease,&#xD;
&#xD;
          -  severe cardiac comorbidity (impaired contractility with ejection fraction &lt; 50%, heart&#xD;
             block, significant arrhythmias, tight valvular lesions),&#xD;
&#xD;
          -  patients undergoing surgery for suspected gynaecological cancer,&#xD;
&#xD;
          -  patients on chronic analgesic medication,&#xD;
&#xD;
          -  inability to comprehend the Visual Analogue Pain Scoring Scale&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Maha Mostafa</last_name>
    <phone>01000365115</phone>
    <email>maha.mostafa@cu.edu.eg</email>
  </overall_contact>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 3, 2022</study_first_submitted>
  <study_first_submitted_qc>November 8, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2022</study_first_posted>
  <last_update_submitted>November 8, 2022</last_update_submitted>
  <last_update_submitted_qc>November 8, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Ahmed Hasanin</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Ketorolac</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>data will be share upon reasonable request from the PI</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

